2-溴-3-氯-5-(三氟甲基)吡啶 | 75806-84-7

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 2-溴-3-氯-5-(三氟甲基)吡啶
• 中文别名: 2-溴-3-氯-5-三氟甲基吡啶；2-溴-3-氯-5-三氟甲基异烟酸
• 英文名称: 2-bromo-3-chloro-5-(trifluoromethyl)pyridine
• 英文别名: 3-chloro-2-bromo-5-trifluoromethylpyridine
• CAS: 75806-84-7
• 化学式: C₆H₂BrClF₃N
• mdl: MFCD00153072
• 分子量: 260.441
• InChiKey: SMTKGMYGLYWNDL-UHFFFAOYSA-N

物化性质

• 沸点：
  88 °C
• 密度：
  1.83

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.166
• 拓扑面积：
  12.9
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 安全说明：
  S26,S37/39
• 危险类别码：
  R36/37/38
• 海关编码：
  2933399090
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335

SDS

Name:	2-Bromo-3-chloro-5-(trifluoromethyl)pyridine, 97% Material Safety Data Sheet
Synonym:
CAS:	75806-84-7

Section 1 - Chemical Product MSDS Name: 2-Bromo-3-chloro-5-(trifluoromethyl)pyridine, 97% Material Safety Data Sheet
Synonym:

---

SECTION 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
75806-84-7	2-Bromo-3-chloro-5-(trifluoromethyl)py	97%	unlisted

+++++
Hazard Symbols: XI

---

SECTION 3 - HAZARDS IDENTIFICATION EMERGENCY OVERVIEW Irritating to eyes, respiratory system and skin. Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
Causes respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

SECTION 4 - FIRST AID MEASURES
Eyes:
Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

SECTION 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

SECTION 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

SECTION 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

SECTION 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low. Exposure Limits CAS# 75806-84-7: Personal Protective Equipment
Eyes:
Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

SECTION 9 - PHYSICAL AND CHEMICAL PROPERTIES
Physical State: Solid
Color: colorless - pale yellow
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C6H2BrClF3N
Molecular Weight: 260

---

SECTION 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Oxidizing agents, bases, amines.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, carbon dioxide, hydrogen fluoride gas, hydrogen bromide, bromine, fluorine.
Hazardous Polymerization: Has not been reported

---

SECTION 11 - TOXICOLOGICAL INFORMATION RTECS#: CAS# 75806-84-7 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
2-Bromo-3-chloro-5-(trifluoromethyl)pyridine - Not listed by ACGIH, IARC, or NTP.

---

SECTION 12 - ECOLOGICAL INFORMATION

---

SECTION 13 - DISPOSAL CONSIDERATIONS Dispose of in a manner consistent with federal, state, and local regulations.

---

SECTION 14 - TRANSPORT INFORMATION IATA No information available. IMO No information available. RID/ADR No information available.

---

SECTION 15 - REGULATORY INFORMATION European/International Regulations European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. S 37/39 Wear suitable gloves and eye/face protection. WGK (Water Danger/Protection) CAS# 75806-84-7: No information available. Canada None of the chemicals in this product are listed on the DSL/NDSL list. CAS# 75806-84-7 is not listed on Canada's Ingredient Disclosure List. US FEDERAL TSCA CAS# 75806-84-7 is not listed on the TSCA inventory. It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
MSDS Creation Date: 3/21/2003 Revision #0 Date: Original. The information above is believed to be accurate and represents the best information currently available to us. However, we make no warranty of merchantability or any other warranty, express or implied, with respect to such information, and we assume no liability resulting from its use. Users should make their own investigations to determine the suitability of the information for their particular purposes. In no way shall the company be liable for any claims, losses, or damages of any third party or for lost profits or any special, indirect, incidental, consequential or exemplary damages, howsoever arising, even if the company has been advised of the possibility of such damages.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-溴-3-氯-5-(三氟甲基)吡啶 在 1,1'-双(二苯膦基)二茂铁二氯化钯(II)二氯甲烷复合物 、 [Rh(OH)(cod)]2 、 chloro(2-dicyclohexylphosphino-2′,6′-diisopropoxy-1,1′-biphenyl)[2-(2-aminoethyl)phenyl]palladium(II) 、 potassium carbonate 、 caesium carbonate 、 2-二环己基磷-2,4,6-三异丙基联苯 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 水 为溶剂， 反应 46.0h， 生成 1-(3-(3-(trifluoromethyl)-10,11-dihydro-5H-benzo[b]pyrido[2,3-f]azepin-5-yl)phenyl)ethanone
  参考文献：
  名称：

  Multicomponent-Multicatalyst Reactions (MC)²R: Efficient Dibenzazepine Synthesis

  摘要：

  A Rh-I/Pd-0 catalyst system was applied to the multicomponent synthesis of aza-dibenzazepines from vinylpyridines, arylboronic acids, and amines in a domino process with no intermediate isolation or purification.

  DOI：

  10.1021/ol4030925
• 作为产物：
  描述：

  2,3-二氯-5-三氟甲基吡啶 在 三甲基溴硅烷 作用下， 反应 15.0h， 以90%的产率得到2-溴-3-氯-5-(三氟甲基)吡啶
  参考文献：
  名称：

  Multicomponent-Multicatalyst Reactions (MC)²R: Efficient Dibenzazepine Synthesis

  摘要：

  A Rh-I/Pd-0 catalyst system was applied to the multicomponent synthesis of aza-dibenzazepines from vinylpyridines, arylboronic acids, and amines in a domino process with no intermediate isolation or purification.

  DOI：

  10.1021/ol4030925

文献信息

• [EN] SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF<br/>[FR] BENZAMIDES SUBSTITUÉS ET LEURS MÉTHODES D'UTILISATION
  申请人：GENENTECH INC

  公开号：WO2015078374A1

  公开（公告）日：2015-06-04

  The invention provides compounds having the general formula I, and pharmaceutically acceptable salts thereof, wherein the variables RA, RAA, subscript n, ring A, X2, L, subscript m, X1, R1, R2, R3, R4, R5, and RN have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.

  这项发明提供了具有一般式I的化合物及其药用盐，其中变量RA、RAA、下标n、环A、X2、L、下标m、X1、R1、R2、R3、R4、R5和RN的含义如本文所述，并包含这种化合物的组合物和使用这种化合物和组合物的方法。
• [EN] BICYCLIC THIAZINE AND OXAZINE DERIVATIVES AS BETA-SECRETASE INHIBITORS AND METHODS OF USE<br/>[FR] DÉRIVÉS DE THIAZINE ET D'OXAZINE BICYCLIQUES EN TANT QU'INHIBITEURS DE BÊTA-SÉCRÉTASE ET PROCÉDÉS D'UTILISATION
  申请人：AMGEN INC

  公开号：WO2018112084A1

  公开（公告）日：2018-06-21

  The present disclosure provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula (I): (Formula (I)) wherein variables X, Y, R2, R3, R4, R5, R6, and n of Formula (I) are defined herein. This disclosure also provides pharmaceutical compositions comprising the compounds, and uses of the compounds and compositions for treatment of disorders and/or conditions related to Aβ plaque formation and deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimer 's disease, cognitive deficits, cognitive impairments, and other central nervous system conditions.

  本公开提供了一类新的化合物，用于调节β-分泌酶（BACE）活性。这些化合物具有一般式（I）：（式（I）），其中式（I）中的变量X、Y、R2、R3、R4、R5、R6和n在此处定义。本公开还提供了包括这些化合物的药物组合物，以及这些化合物和组合物用于治疗与Aβ斑块形成和沉积相关的疾病和/或症状的用途，这些疾病和症状是由BACE的生物活性引起的。这种由BACE介导的疾病包括阿尔茨海默病、认知缺陷、认知障碍和其他中枢神经系统疾病。
• [EN] 1,4-THIAZINE DIOXIDE AND 1,2,4-THIADIAZINE DIOXIDE DERIVATIVES AS BETA-SECRETASE INHIBITORS AND METHODS OF USE<br/>[FR] DÉRIVÉS DE DIOXYDE DE 1,4-THIAZINE ET DE DIOXYDE DE 1,2,4-THIADIAZINE EN TANT QU'INHIBITEURS DE BÊTA-SÉCRÉTASE ET PROCÉDÉS D'UTILISATION
  申请人：AMGEN INC

  公开号：WO2018112094A1

  公开（公告）日：2018-06-21

  The present disclosure provides a class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I: wherein variables A, X, R2, R2', R3, R4, R5, R6, and R7 of Formula I are defined herein. This disclosure also provides pharmaceutical compositions comprising the compounds, and uses of the compounds and compositions for treatment of disorders and/or conditions related to Aβ plaque formation and deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairments, and other central nervous system conditions.

  本公开提供了一类化合物，用于调节β-分泌酶（BACE）活性。这些化合物具有一般的化学式I：其中化学式I中的变量A、X、R2、R2'、R3、R4、R5、R6和R7在此处定义。本公开还提供了包含这些化合物的药物组合物，以及这些化合物和组合物用于治疗与Aβ斑块形成和沉积相关的疾病和/或症状的用途，这些疾病和症状是由BACE的生物活性引起的。这种由BACE介导的疾病包括阿尔茨海默病、认知缺陷、认知障碍和其他中枢神经系统疾病。
• TRICYCLIC COMPOUNDS AND USE THEREOF
  申请人：Aso Kazuyoshi

  公开号：US20090186879A1

  公开（公告）日：2009-07-23

  There is provided a compound of the formula (I′): wherein x is a nitrogen or CRx, Rx is a hydrogen, etc., R 1 is an optionally substituted hydrocarbon group, etc., R 2 is an optionally substituted hydrocarbon group, etc., ring A is 5- to 8-membered heterocyclic ring, etc., and each of Y 1 , Y 2 and Y 3 is an optionally substituted carbon or a nitrogen, etc.; or a salt thereof or a prodrug thereof, which have CRF receptor antagonistic activity and use thereof.

  提供了一个公式(I′)的化合物：其中x是氮或CRx，Rx是氢等，R1是可选择地取代的碳氢基团等，R2是可选择地取代的碳氢基团等，环A是5-至8-成员的杂环环，等等，Y1、Y2和Y3中的每一个是可选择地取代的碳或氮等；或其盐或前药，具有CRF受体拮抗活性及其用途。
• 一种3-氯-2-氰基-5-三氟甲基吡啶的制备方 法
  申请人：山东省联合农药工业有限公司

  公开号：CN106349159B

  公开（公告）日：2019-03-22

  本发明公开了一种3‑氯‑2‑氰基‑5‑三氟甲基吡啶的制备方法，包括以下步骤：①将3‑氯‑2‑R基‑5‑三氟甲基吡啶溶于溶剂A中，然后向其中加入活化剂，加热回流4~6小时，降温至20~30℃，得到反应液，将所得反应液过滤，得到滤饼，将所得滤饼于40~50℃下真空干燥1~2小时，得到有机盐；②将步骤①所得有机盐、氰化物加入到溶剂B和水中，在0~80℃下搅拌反应2~3小时，得到混合液，将所得混合液静置分层，得到有机相a；将所得有机相a加入盐酸调节其pH为2~4后静置分层，得到酸水层和有机层，将所得有机层加水洗涤至pH至6~7，得到洗涤后的水和有机相b；本发明的制备工艺避免了乙腈和丙腈等腈类溶剂，而使用与水几乎不溶的二氯甲烷等低毒溶剂，构思巧妙，能对溶剂进行回收重复利用，从而降低了生产成本，减少了环境污染。